Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Venina Isabel Poço Viana Leme de Barros"
We found (4) results for your search.
, , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS02
, , , , , , •The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens.
•Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone.
•Progestogen-only pills do not confer an increased risk of VTE.
•Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years.
•Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years.
•Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT).
•Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization.
•The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric.
•Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy.
•Postmenopausal HT increases the risk of thrombosis at atypical sites.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS02
, , , , , , •The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens.
•Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone.
•Progestogen-only pills do not confer an increased risk of VTE.
•Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years.
•Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years.
•Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT).
•Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization.
•The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric.
•Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy.
•Postmenopausal HT increases the risk of thrombosis at atypical sites.
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(6):495-501
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(6):495-501
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2014;36(2):50-55
DOI 10.1590/S0100-72032014000200002
To evaluate pregnancy outcome and thrombophilia frequency in women with recurrent
fetal death.
Evaluation of obstetric outcomes in a retrospective cohort of pregnant women with
recurrent stillbirth after the 20th week, from 2001 to 2013.
Antithrombin activity, protein C and S activity, factor V Leiden, prothrombin gene
mutation and antiphospholipid syndrome were analyzed.
We included 20 patients who had recurrent fetal death. Thrombophilia were found
in 11 of them, 7 diagnosed with antiphospholipid syndrome, 3 with protein S
deficiency and 1 with prothrombin gene mutation. All of them were treated with
subcutaneous heparin (unfractionated heparin or enoxaparina) and 14 of them with
acetylsalicylic acid (AAS) during pregnancy. Obstetric complications occurred in
15 patients and included: intrauterine fetal growth restriction (25%), placenta
previa (15%), reduced amniotic fluid index (25%), severe preeclampsia (10%), fetal
distress (5%), and stillbirth (5%). The mean gestational age at delivery was
35.8±3.7 weeks and newborn weight averaged 2,417.3±666.2 g.
Thrombophilia screening should be performed in all pregnant women with recurrent
fetal death after the 20th week as a way to identify possible causal
factors suitable for treatment.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2014;36(2):50-55
DOI 10.1590/S0100-72032014000200002
To evaluate pregnancy outcome and thrombophilia frequency in women with recurrent
fetal death.
Evaluation of obstetric outcomes in a retrospective cohort of pregnant women with
recurrent stillbirth after the 20th week, from 2001 to 2013.
Antithrombin activity, protein C and S activity, factor V Leiden, prothrombin gene
mutation and antiphospholipid syndrome were analyzed.
We included 20 patients who had recurrent fetal death. Thrombophilia were found
in 11 of them, 7 diagnosed with antiphospholipid syndrome, 3 with protein S
deficiency and 1 with prothrombin gene mutation. All of them were treated with
subcutaneous heparin (unfractionated heparin or enoxaparina) and 14 of them with
acetylsalicylic acid (AAS) during pregnancy. Obstetric complications occurred in
15 patients and included: intrauterine fetal growth restriction (25%), placenta
previa (15%), reduced amniotic fluid index (25%), severe preeclampsia (10%), fetal
distress (5%), and stillbirth (5%). The mean gestational age at delivery was
35.8±3.7 weeks and newborn weight averaged 2,417.3±666.2 g.
Thrombophilia screening should be performed in all pregnant women with recurrent
fetal death after the 20th week as a way to identify possible causal
factors suitable for treatment.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1999;21(4):215-221
DOI 10.1590/S0100-72031999000400006
Purpose: to determine the effectiveness and the safety of treatment with heparin and low-dose aspirin in pregnant women with antiphospholipid syndrome, and to determine possible deteriorating factors for this syndrome. Methods: 17 patients with antiphospholipid syndrome were submitted to a rigorous antenatal care. Patients were treated with a fixed dose of heparin (10,000 IU/day) associated with low-dose aspirin (100 mg/day). We analyzed perinatal and maternal results, using chi² test and Fischer's exact test. Results: the overall live birth rate was 88.2% in treated pregnancies of these patients versus 13.3% of their previous nontreated pregnancies. The incidence of adverse pregnancy outcomes was very significant: oligohydramnios (40%), fetal distress (33.3%), fetal growth retardation (33.3%), gestational diabetes (29.4%), preeclampsia(23.5%), and preterm delivery (60%). The presence of systemic lupus erythematosus was an indication of poor prognosis. No significant side effects were observed during the treatment. Conclusions: this treatment was effective to improve live birth rate, safe, but it was not able to avoid adverse pregnancy outcomes associated with antiphospholipid syndrome. Systemic lupus erythematosus was a deteriorating factor for this syndrome.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1999;21(4):215-221
DOI 10.1590/S0100-72031999000400006
Purpose: to determine the effectiveness and the safety of treatment with heparin and low-dose aspirin in pregnant women with antiphospholipid syndrome, and to determine possible deteriorating factors for this syndrome. Methods: 17 patients with antiphospholipid syndrome were submitted to a rigorous antenatal care. Patients were treated with a fixed dose of heparin (10,000 IU/day) associated with low-dose aspirin (100 mg/day). We analyzed perinatal and maternal results, using chi² test and Fischer's exact test. Results: the overall live birth rate was 88.2% in treated pregnancies of these patients versus 13.3% of their previous nontreated pregnancies. The incidence of adverse pregnancy outcomes was very significant: oligohydramnios (40%), fetal distress (33.3%), fetal growth retardation (33.3%), gestational diabetes (29.4%), preeclampsia(23.5%), and preterm delivery (60%). The presence of systemic lupus erythematosus was an indication of poor prognosis. No significant side effects were observed during the treatment. Conclusions: this treatment was effective to improve live birth rate, safe, but it was not able to avoid adverse pregnancy outcomes associated with antiphospholipid syndrome. Systemic lupus erythematosus was a deteriorating factor for this syndrome.
